GenVac names new director
This article was originally published in Scrip
Executive Summary
GenVec, a clinical-stage biopharmaceutical company focused on using its adenovector gene delivery platform to develop a pipeline of therapeutics and vaccines, has named Michael Richman to its board of directors. Mr Richman has been president and CEO of Amplimmune, a member of the AstraZeneca group since 2013.